Mesa Laboratories Inc (MLAB)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Mesa Laboratories Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 5 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 100.80 $ — 84% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
5 of 10 Solid growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 4.4% failed
- More than 10% revenue growth is expected for the coming year 5.0% failed
- Share count grows by less than 3% a year 1.3% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 19.3% failed
- Gross margin at 40% or higher and without meaningful erosion 63.5% passed
- Goodwill from acquisitions does not grow faster than revenue 43.7% passed
- Net debt below twice EBITDA 4.0 x EBITDA failed
- Operating cash flow covers the profits of the last three years 383 m passed
- Return on capital at 15% or higher, or up versus two years ago 5.1% passed
- Insiders hold at least 10% or are net buyers 5.7% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Analysts & Price Target
The price target sits 11.1% above the current price.
- Consensus
- Hold
- Analyst Ratings
- 4
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 03/31/2027 | 11.62 | 11.62 – 11.62 | 259 | 39.3% | 1 |
| 03/31/2028 | 12.27 | 12.27 – 12.27 | 272 | 5.6% | 1 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 2.55 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.31 | -178.70 | 63 | 17.50 | -2.70 | 18 | 18 |
| 2025: Q1 | -1.31 | – | 62 | 5.50 | -11.40 | 13 | 12 |
| 2025: Q2 | 0.85 | 36.70 | 60 | 2.40 | 8.00 | 2 | 1 |
| 2025: Q3 | 0.45 | -28.60 | 61 | 5.00 | 4.10 | 8 | 7 |
| 2025: Q4 | 0.65 | – | 65 | 3.60 | 5.60 | 19 | 18 |
| 2026: Q1 | -0.75 | – | 64 | 2.60 | -6.50 | 14 | 17 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2017 | 94 | 16 | 11 | 2.91 | 8 | 98 | 172 |
| 2018 | 96 | 2 | -3 | -0.79 | 25 | 99 | 164 |
| 2019 | 103 | 10 | 7 | 1.86 | 31 | 111 | 157 |
| 2020 | 118 | 8 | 2 | 0.41 | 27 | 220 | 420 |
| 2021 | 134 | 12 | 3 | 0.64 | 37 | 406 | 601 |
| 2022 | 184 | 5 | 2 | 0.35 | 39 | 394 | 707 |
| 2023 | 219 | 3 | 1 | 0.17 | 28 | 393 | 662 |
| 2024 | 216 | -272 | -254 | -47.21 | 44 | 145 | 447 |
| 2025 | 241 | 16 | -2 | -0.36 | 47 | 160 | 433 |
| 2026 | 249 | 19 | 7 | 1.21 | 43 | 186 | 428 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Mesa Laboratories, Inc. entwickelt, entwirft, fertigt, verkauft und wartet Life-Sciences-Werkzeuge und Qualitätskontrollprodukte und -dienstleistungen in Nordamerika, Europa, im asiatisch-pazifischen Raum und international.
| Employees | 717 |
|---|---|
| Headquarters | Lakewood, CO |
| Address | 12100 West Sixth Avenue, 80228 Lakewood, United States |
| Phone | 303 987 8000 |
| Website | mesalabs.com |
| IPO Date | 25. Jan 1995 |
| ISIN | US59064R1095 |
Management
| Name | Title | Birth Year |
|---|---|---|
| John V. Sakys CPA | VP & CFO | 1969 |
| Siddhartha Chandrakant Kadia B.E., M.S., Ph.D. | CEO, President & Director | 1970 |
| Lyndsey Crennen | Chief Accounting Officer | 1985 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.